Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Brian G.M. Durie, Annette Lam, Mai Ngo, Huiling Pei, Eric M. Ammann

Blood (2022) 140 (Supplement 1): 10009–10010.

https://doi.org/10.1182/blood-2022-165591

Published: 2022

Journal Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar

Blood (2021) 138 (Supplement 1): 118.

https://doi.org/10.1182/blood-2021-144914

Published: 2021

Journal Articles

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

Jianming He, Heather Berringer, Bart Heeg, Tobias Kampfenkel, Harikumaran R. Dwarakanathan, Stephen Johnston, João Mendes, Annette Lam, Sacheeta Bathija, Eric Mackay

Blood (2021) 138 (Supplement 1): 4083.

https://doi.org/10.1182/blood-2021-146044

Published: 2021

Journal Articles

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Angela Dispenzieri, MD, Jeff Zonder, MD, James Hoffman, MD, Sandy W. Wong, MD, Michaela Liedtke, MD, Rafat Abonour, MD, Anita D'Souza, MBBS, Charlene Lee, MSc, Sandhya Nair, PhD MSc, Ravi Potluri, PGDM, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Annette Lam, MSc, Maneesha Mehra, MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140405

Published: 2020

Journal Articles

Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Mary Slavcev, Allison Spinelli, MSc, Elisabeth Absalon, Tara Masterson, MSc, Chris Heuck, MD, Annette Lam, MSc, Erwin De Cock, MSc

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-139995

Published: 2020

Journal Articles

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Eric M. Ammann, PhD, Annette Lam, MSc, Wenze Tang, MPH, Tobias Kampfenkel, MD, Mohit Sharma, Charlene Lee, MSc, Shuchita Kaila, PhD, Alex Z. Fu, PhD, Kathleen Gray, PhD, Jianming He, PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-139882

Published: 2020

Journal Articles

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Brian G.M. Durie, MD, Shaji K. Kumar, MD, Saad Z. Usmani, MD, Bareng A.S. Nonyane, Eric A. Ammann, Annette Lam, Rachel Kobos, MD, Eric M Maiese, PhD, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 1830.

https://doi.org/10.1182/blood-2019-122937

Published: 2019

Journal Articles

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Vania T.M. Hungria, MD PhD, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, MD, Michele Cavo, Bart Heeg, PhD, Annette Lam, Gerardo Machnicki, Jianming He, PhD, Mariana Fernandez

Blood (2019) 134 (Supplement_1): 2143.

https://doi.org/10.1182/blood-2019-123557

Published: 2019

Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD

Blood (2019) 134 (Supplement_1): 2144.

https://doi.org/10.1182/blood-2019-123561

Published: 2019

Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 4740.

https://doi.org/10.1182/blood-2019-123491

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Michele Cavo, MD, Meletios A Dimopoulos, MD, Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Andrzej Jakubowiak, MD PhD, William Deraedt, Annette Lam, Tobias Kampfenkel, MD, Ming Qi, MD PhD, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2018-99-113128

Published: 2018

Journal Articles

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

Rafael Fonseca, MD, Saad Z. Usmani, MD, Maneesha Mehra, Mary Slavcev, Jon Ukropec, PhD, Annette Lam, Ravi Potluri

Blood (2018) 132 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2018-99-113125

Published: 2018

Journal Articles

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Meletios A Dimopoulos, MD, Michele Cavo, MD, Maria-Victoria Mateos, MD PhD, Thierry Facon, Bart Heeg, PhD, Sophie van Beekhuizen, Sandhya Nair, Marta Pisini, MBA, Annette Lam, Mary Slavcev

Blood (2018) 132 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2018-99-113517

Published: 2018

Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2018-99-113157

Published: 2018

Journal Articles

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Hervé Avet-Loiseau, MD PhD, Jianming He, PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Sourish Saha, Christopher Chiu, PhD, Sarah Cote, Annette Lam

Blood (2018) 132 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2018-99-113571

Published: 2018

Journal Articles

Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment

Ajai Chari, MD, Maneesha Mehra, Mary Slavcev, Annette Lam, Ravi Potluri, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2018-99-113176

Published: 2018

Journal Articles

Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis

Jesus F San-Miguel, MD PhD, Thierry Facon, Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Bart Heeg, PhD, Sophie van Beekhuizen, Marta Pisini, MBA, Sandhya Nair, Annette Lam, Mary Slavcev

Blood (2018) 132 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2018-99-113668

Published: 2018

Journal Articles

Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Jon Ukropec, Ravi Potluri, Anandaroop Dasgupta

Blood (2017) 130 (Supplement 1): 3093.

https://doi.org/10.1182/blood.V130.Suppl_1.3093.3093

Published: 2017

Journal Articles

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Ravi Potluri, Anandaroop Dasgupta

Blood (2017) 130 (Supplement 1): 3094.

https://doi.org/10.1182/blood.V130.Suppl_1.3094.3094

Published: 2017

NARROW

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment

Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis

Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only